Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer

Author:

Govindan Ramaswamy1,Senan Suresh2,Dickgreber Nicolas3,Provencio Mariano4,Wu Yi-Long5,Syrigos Konstantinos6,Parente Barbara7,Wilson Michele8,Ziemiecki Ryan9,Chouaki Nadia10,Hossain Anwar11,San Antonio Belén12,Winfree Katherine11,Vokes Everett E.13

Affiliation:

1. Department of Medical Oncology, Washington University School of Medicine, Saint Louis, MO, USA;

2. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands;

3. Department of Pulmonology, Mathias – Spital Rheine, Rheine, Germany;

4. Department of Medical Oncology, Hospital Puerta de Hierro, Madrid, Spain;

5. Department of Lung Cancer, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China;

6. Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece;

7. Department of Pulmonology, Hospital CUF Porto, Porto, Portugal;

8. Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA;

9. Department of Biostatistics, RTI Health Solutions, Research Triangle Park, NC, USA;

10. Eli Lilly and Company, Neuilly-sur-Seine, France;

11. Eli Lilly and Company, Indianapolis, IN, USA;

12. Lilly España, Madrid, Spain;

13. Department of Medicine, University of Chicago, Chicago, IL, USA

Funder

Eli Lilly and Company

ClinicalTrials.gov identifier:

Publisher

Informa UK Limited

Subject

General Medicine

Reference17 articles.

1. International Association for the Study of Lung Cancer. Lung Cancer Fact Sheet – 2016 – Europe [Internet] [cited 2017 Mar 10]. Available from: https://www.iaslc.org/lung-cancer-fact-sheet-2016-asia

2. Key Statistics for Lung Cancer [Internet] [cited 2016 Sep 21]. Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics

3. Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

4. Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis

5. Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. New developments in locally advanced nonsmall cell lung cancer;European Respiratory Review;2021-05-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3